AFP and hepatocellular carcinoma: Additionally, the anti-VEGF treatment with Ramucirumab is approved as second-line treatment for HCC patients who progressed on first-line Sora, if serum α-fetoprotein (AFP) levels exceed 400 ng/mL (6).